Stock-Based Compensation, Restricted Stock and Stock Options: (Tables)

6 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Schedule of stock based compensation expenses

	Three months ended September 30,				Six months ended September 30,
	2019		2018		2019		2018
Research and development expenses	$	722,606	$	115,290	$	981,515	$	232,846
Selling, general and administrative expenses		1,046,816		115,707		1,884,850		204,286
Total stock-based compensation	$	1,769,422	$	230,997	$	2,866,365	$	437,132

Schedule of restricted stock awards

	Number of Shares			Weighted Average Grant-Date  Fair Value
Unvested at March 31, 2019		-		$	-
Granted		6,000,000		$	0.82
Vested		(749,997	)	$	0.82
Unvested at September 30, 2019 (Unaudited)		5,250,003		$	0.82

Schedule of stock options

	Shares Underlying Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual  Term (Years)		Aggregate Intrinsic Value
Outstanding at March 31, 2019		5,813,500	$	0.18		9.2	$	3,720,395
Outstanding at September 30, 2019 (Unaudited)		5,813,500	$	0.18		8.7	$	3,313,450
Exercisable at September 30, 2019 (Unaudited)		2,560,092	$	0.19		8.7	$	1,435,611